About Aytu BioPharma
Aytu BioPharma is a publicly listed company based in Englewood (United States) founded in 2002 by Joshua Disbrow. Prescription therapeutics for ADHD and prevalent conditions are developed. It operates on a Direct-to-Consumer (D2C) model. The company has 102 employees. Aytu BioPharma has completed 3 acquisitions, including Innovus Pharma, Nuelle and ProstaScintscan.com. Its chief executive, as recorded, is Joshua Disbrow. Aytu BioPharma offers products and services including EXXUA™, ADHD Portfolio, and Pediatric Portfolio. Its focus areas include Pharmaceuticals and CNS Therapeutics.
Company details
Aytu BioPharma is engaged in developing and providing innovative medicines for complex central nervous system (CNS) diseases. The company targets conditions such as major depressive disorder (MDD) and attention deficithyperactivity disorder (ADHD). Solutions are designed to enhance patient quality of life through novel therapeutics. Access to these medicines is ensured by prioritizing patient needs and implementing bold strategies. The healthcare sector is primarily served, with a commitment to psychiatric condition management.
- Headquarters Englewood, United States
- Employees 102
- Founders Joshua Disbrow
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website aytubio.com
- Social LinkedIn X Facebook
- Legal Name Aytu Biopharma, Inc.
- Annual Revenue$57.57 M (USD)-13.27as on Jun 30, 2026
- Net Profit-$14.25 M (USD)-5.09as on Jun 30, 2026
- EBITDA-$4.38 M (USD)-155.41as on Jun 30, 2026
- Latest Funding Round$20M (USD), Post-IPO
Mar 2020
- InvestorsTauriga Sciences
& 2 more
- Employee Count102
- Investments & AcquisitionsInnovus Pharma
& 2 more
Products & Services of Aytu BioPharma
Aytu BioPharma offers a comprehensive portfolio of products and services, including EXXUA™, ADHD Portfolio, and Pediatric Portfolio.
Innovative treatment developed for major depressive disorder patients.
Therapeutics designed for attention deficit hyperactivity disorder management.
Medicines created for pediatric patients with specific needs.
Funding Insights of Aytu BioPharma
- Total Rounds 10
- Last Round Post-IPO — $20M
- Investors Count 3
All 10 funding rounds of Aytu BioPharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2020 | $20M | Post-IPO | – | – | – |
| Mar 2020 | $9M | Post-IPO | – | – | – |
| Oct 2019 | $10M | Post-IPO | – | – | |
| Mar 2018 | $12M | Post-IPO | – | – | |
| Mar 2018 | $70,739 | Post-IPO | – | – | |
| Aug 2017 | $11.84M | Post-IPO | – | – | – |
| Sep 2015 | $5.18M | Post-IPO | – | – | – |
| Feb 2011 | Post-IPO | – | – | – | |
| Jul 2010 | Post-IPO | – | – | – | |
| Feb 2009 | Post-IPO | – | – | – |
3 investors in total: 3 institutional.
Investors in Aytu BioPharma
Aytu BioPharma has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Tauriga Sciences, Armistice Capital and Altium Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Long-term investments in healthcare companies are managed by Altium Capital. | 2017 | altiumcap.com | New York, United States | |
Global hedge fund managing long/short investments in health care and consumer sectors. | 2012 | armisticecapital.com | New York, United States | |
Cannabis-based medicinal products are manufactured for therapeutic use. | 2001 | tauriga.com | Danbury, United States |
Investor details for Aytu BioPharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aytu BioPharma
29 people are tracked at Aytu BioPharma (9 in leadership, 5 in board & advisors, 15 in team); the tracked headcount is 102.
| Name | Role | Group |
|---|---|---|
Joshua Disbrow | Co-Founder & CEO | Leadership |
Josh Disbrow | Chairman & CEO | Leadership |
Greg Pyszczymuka | Chief Commercial Officer | Leadership |
Tyler Harrington | Vice President Of Marketing And Portfolio Strategy | Leadership |
Tommy H. | Senior Director, Commercial Insights & Sales Operations | Leadership |
Anita Brandon | Director, Marketing Operations | Leadership |
Fei Gao | Director Of Accounting | Leadership |
Luke Schafer | Director Of Financial Reporting And Technical Accounting | Leadership |
Jonathan Hughes | Vice President, Consumer Marketing | Leadership |
Steven Boyd | Director | Board & advisors |
John Donofrio | Director | Board & advisors |
Vivian Liu | Director | Board & advisors |
Carl Dockery | Director | Board & advisors |
Abhinav Jain | Independent Director | Board & advisors |
Ryan Selhorn | EVP of Finance & Business Optimization | Team |
Bianca Morales | Senior Accountant - Reveue Specialist | Team |
Jarrett Disbrow | EVP, Corporate Development | Team |
Russ McMahen | SVP of Research & Development | Team |
Nicki Derksen | Senior Territory Sales Manager | Team |
Charlotte Ball | Manager Of AP & Payroll Administration | Team |
9 more people are available in the full profile.
Complete people profiles for Aytu BioPharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Aytu BioPharma
Aytu BioPharma is a publicly listed company on the NASDAQ with ticker symbol AYTU in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Apr 2021
- Listed onLSE: 0A8M
- Listed entityAytu BioPharma, Inc.
- Exchange sectorHealth technology
- ISINUS0547548588
- Share price$1.99 (+1.02% on the day) · 2026-10-13
- Market capitalisation$21.6M
- EPS (diluted, trailing year)$-1.67
- Volume (last session)24,555
Financials of Aytu BioPharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | $57.6M | -$14.2M | -$4.4M |
| 2025 | $66.4M | -$13.6M | $7.9M |
| 2024 | $65.2M | -$15.8M | $7.3M |
| 2023 | $107.4M | -$17.1M | -$3.5M |
| 2022 | $96.7M | -$108.8M | -$28.0M |
Detailed financial statements for Aytu BioPharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aytu BioPharma
Aytu BioPharma has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Innovus Pharma, Nuelle and ProstaScintscan.com.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Science-backed dietary supplements are developed for everyday wellness. | innovuspharma.com | San Diego, United States | 2011 | Sep 2019 | $8M | |
Therapeutic devices for sexual health and wellness are provided. | nuelle.com | Mountain View, United States | 2012 | May 2017 | •••• | |
Information on diagnostic imaging agents is provided through the website. | prostascintscan.com | 0 | Jun 2015 | •••• |
Complete acquisition details for Aytu BioPharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Aytu BioPharma
7 dated milestones of Aytu BioPharma across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Aytu BioPharma is founded.
- Funding First funding round.
- Acquisition Acquires ProstaScintscan.com.
- Acquisition Acquires Nuelle.
- Acquisition Acquires Innovus Pharma.
- Funding Latest funding round, Post-IPO, of $20.0M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Aytu BioPharma
The website of Aytu BioPharma (aytubio.com) receives about 4.3K visits a month.
- Monthly visits4.3K
▲ 14.1% vs previous month
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Aytu BioPharma (Traditional Health & Nutrition) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | USD 3.02 B | 8,300 | ||
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | USD 5.1 B | 13,500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aytu Biopharma
Complete news archive for Aytu BioPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aytu BioPharma
Aytu BioPharma was founded in 2002 and raised its 1st funding round 7 years after it was founded.
Aytu BioPharma is headquartered in Englewood, United States. It is registered at Englewood, New Jersey, United States.
Joshua Disbrow is the CEO of Aytu BioPharma, as recorded in our data. They have also founded this company.
Aytu BioPharma has 102 employees.
Annual revenue of Aytu BioPharma is $57.57M as on Jun 30, 2026.
Aytu BioPharma is engaged in developing and providing innovative medicines for complex central nervous system (CNS) diseases. The company targets conditions such as major depressive disorder (MDD) and attention deficithyperactivity disorder (ADHD). Solutions are designed to enhance patient quality of life through novel therapeutics. Access to these medicines is ensured by prioritizing patient needs and implementing bold strategies. The healthcare sector is primarily served, with a commitment to psychiatric condition management.
Aytu BioPharma offers EXXUA™, ADHD Portfolio, and Pediatric Portfolio.
Yes, Aytu BioPharma is publicly traded on NASDAQ under the ticker symbol AYTU.
Aytu BioPharma has made 3 acquisitions, including Innovus Pharma, Nuelle, and ProstaScintscan.com.
Aytu BioPharma has 3 investors. Key investors include Tauriga Sciences, Armistice Capital, and Altium Capital Management.
Aytu BioPharma operates through Aytu Biopharma.